

---

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

REPORT OF FOREIGN ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE  
SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2009  
\_\_\_\_\_

Commission File Number: 001-32371  
\_\_\_\_\_

SINOVAC BIOTECH LTD.

39 Shangdi Xi Road  
Haidian District  
Beijing 100085, People's Republic of China  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)  
(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)  
(7): \_\_\_\_\_

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

82- N/A

---

SINOVAC BIOTECH LTD.

Form 6-K

TABLE OF CONTENTS

	<u>Page</u>
Signature	3
Exhibit 99.1 – Press Release	4

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SINOVAC BIOTECH LTD.

By: /s/ Weidong Yin

Name: Weidong Yin

Title: Chief Executive Officer, President

Date: June 9, 2009

---



## Sinovac Schedules 2008 Annual General Meeting

BEIJING, June 10 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2008 Annual General Meeting on Thursday, July 16, 2009 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC and at No. 6 Temple Street, St. John's, Antigua. All shareholders of record as of May 27, 2009 will be eligible to vote and are invited to attend. Sinovac 2008 annual report and the proxy statements are also be available at the company's website: <http://www.sinovac.com/Investors/SECFilings/> and <http://www.sinovac.com/Investors/IRHome/presentation/>.

### About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), and Anflu® (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

### Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang  
Sinovac Biotech Ltd.  
Tel: +86-10-8289-0088 x9871  
Fax: +86-10-6296-6910  
Email: [info@sinovac.com](mailto:info@sinovac.com)

---

Investors:

Amy Glynn/Sara Pellegrino

The Ruth Group

Tel: +1-646-536-7023/7002

Email: [aglynn@theruthgroup.com](mailto:aglynn@theruthgroup.com)

[spellegrino@theruthgroup.com](mailto:spellegrino@theruthgroup.com)

Media:

Janine McCargo

The Ruth Group

Tel: +1-656-536-7033

Email: [jmccargo@theruthgroup.com](mailto:jmccargo@theruthgroup.com)

---

